Clinical trials: Advanced Tumor
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Germ Cell Tumors, Measurable Disease
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent…
- Trial name
- Pazotest-01 (NCT01743482)
- Testing
- Pazopanib
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment.
- Trial name
- NCT00420524
- Testing
- Patupilone/EPO906
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules.
- Trial name
- NCT02116959
- Testing
- Melphalan, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Advanced Solid Tumor
A Study of SHR-1802 in Patients With Advanced Solid Tumor
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess…
- Trial name
- NCT05208177
- Testing
- SHR-1802＋camrelizumab + famitinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed.
- Conditions
- Indolent B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinaemia
- Trial name
- NCT01805375
- Testing
- DI-B4
- Where
- 5 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Cancer Research UK
Non-Small Cell Lung Cancer
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung…
- Trial name
- CKD-702 (NCT04667975)
- Testing
- CKD-702
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Non-small Cell Lung Cancer
Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
This is a phase I/II, open-label and multi-center study of SY-3505, a third-generation ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer (ALK-positive NSCLC).
- Trial name
- NCT05257512
- Testing
- SY-3505
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer…
- Trial name
- PRECIOUS (NCT02514681)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Japan Breast Cancer Research Group
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00119236
- Testing
- tanespimycin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Hepatocellular Carcinoma
Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
To date, Sorafenib is the only drug therapy to have demonstrated a benefit in overall survival in patients with advanced or metastatic hepatocellular carcinoma.
- Trial name
- PharmacoCHC (NCT03340636)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Tumors
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced…
- Trial name
- NCT00395434
- Testing
- Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen…
- Conditions
- Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT04510064
- Testing
- Camrelizumab plus mFLOT regimen, R0 surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
This phase II MATCH treatment trial identifies the effects of nivolumab in patients whose cancer has a genetic change called mismatch repair deficiency.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439214
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.
- Trial name
- NCT04324814
- Testing
- SHR-1701
- Where
- 4 sites in Australia
- Volunteers
- 41 people
- Sponsor
- Atridia Pty Ltd.
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests.
- Trial name
- FACT (NCT02390947)
- Testing
- Famitinib
- Where
- 44 sites in China
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005638
- Testing
- cisplatin, irinotecan hydrochloride, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.